PLAAT5

Summary

PLAAT5 (phospholipase A and acyltransferase 5, HGNC:24978) is a protein-coding gene on chromosome 11q12.3, encoding Phospholipase A and acyltransferase 5 (Q96KN8). Exhibits both phospholipase A1/2 and acyltransferase activities.

Enables N-acyltransferase activity; phospholipase A1 activity; and phospholipase A2 activity. Acts upstream of or within N-acylphosphatidylethanolamine metabolic process. Predicted to be located in cytosol. Predicted to be active in cytoplasm.

Source: NCBI Gene 117245 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 38 total
• Druggable target: yes
• MANE Select transcript: NM_001146729

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24978
Approved symbol	PLAAT5
Name	phospholipase A and acyltransferase 5
Location	11q12.3
Locus type	gene with protein product
Status	Approved
Aliases	HRLP5, iNAT, PLAAT-5
Ensembl gene	ENSG00000168004
Ensembl biotype	protein_coding
OMIM	611474
Entrez	117245

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 nonsense_mediated_decay

ENST00000301790, ENST00000394615, ENST00000536887, ENST00000538712, ENST00000539221, ENST00000540857, ENST00000906933, ENST00000906934

RefSeq mRNA: 3 — MANE Select: NM_001146729 NM_001146728, NM_001146729, NM_054108

CCDS: CCDS53646, CCDS53647, CCDS8044

Canonical transcript exons

ENST00000540857 — 6 exons

Exon	Start	End
ENSE00002233409	63461404	63463595
ENSE00002254386	63490243	63490333
ENSE00002278246	63490887	63491167
ENSE00003469960	63468357	63468465
ENSE00003581323	63488871	63488976
ENSE00003616701	63466110	63466372

Expression profiles

Bgee: expression breadth ubiquitous, 182 present calls, max score 96.81.

FANTOM5 (CAGE): breadth broad, TPM avg 1.7973 / max 185.3959, expressed in 317 samples.

FANTOM5 promoters (9 alternative TSS)

Promoter ID	TPM avg	Samples expressed
120283	1.0516	259
120286	0.3175	119
120282	0.1034	39
120287	0.0907	37
120280	0.0695	44
120284	0.0583	26
120281	0.0548	25
120285	0.0408	17
120279	0.0107	4

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sperm	CL:0000019	96.81	gold quality
left testis	UBERON:0004533	95.29	gold quality
right testis	UBERON:0004534	94.93	gold quality
testis	UBERON:0000473	93.85	gold quality
adipose tissue	UBERON:0001013	86.96	gold quality
subcutaneous adipose tissue	UBERON:0002190	85.70	gold quality
adipose tissue of abdominal region	UBERON:0007808	84.88	gold quality
omental fat pad	UBERON:0010414	84.39	gold quality
peritoneum	UBERON:0002358	84.33	gold quality
kidney epithelium	UBERON:0004819	83.85	gold quality
adult organism	UBERON:0007023	81.33	gold quality
body of pancreas	UBERON:0001150	80.96	gold quality
left ventricle myocardium	UBERON:0006566	80.51	gold quality
cardiac muscle of right atrium	UBERON:0003379	80.38	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	80.26	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.82	gold quality
spinal cord	UBERON:0002240	78.63	gold quality
tibial nerve	UBERON:0001323	78.08	gold quality
mucosa of stomach	UBERON:0001199	77.83	gold quality
parietal pleura	UBERON:0002400	77.33	gold quality
thoracic mammary gland	UBERON:0005200	76.27	gold quality
mammary gland	UBERON:0001911	76.15	gold quality
oocyte	CL:0000023	75.91	gold quality
secondary oocyte	CL:0000655	75.89	gold quality
amygdala	UBERON:0001876	74.29	gold quality
prefrontal cortex	UBERON:0000451	74.08	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	73.40	gold quality
left uterine tube	UBERON:0001303	72.76	gold quality
lower esophagus muscularis layer	UBERON:0035833	72.65	gold quality
lower esophagus	UBERON:0013473	72.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.74

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

83 targeting PLAAT5, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-12133	99.92	71.82	2006

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	lratb.2	ENSDARG00000077652
mus_musculus	Plaat5	ENSMUSG00000024973
rattus_norvegicus	Plaat5	ENSRNOG00000023528

Paralogs (7): LRAT (ENSG00000121207), PLAAT1 (ENSG00000127252), PLAAT4 (ENSG00000133321), PLAAT2 (ENSG00000133328), LRATD1 (ENSG00000162981), LRATD2 (ENSG00000168672), PLAAT3 (ENSG00000176485)

Protein

Protein identifiers

Phospholipase A and acyltransferase 5 — Q96KN8 (reviewed: Q96KN8)

Alternative names: Ca(2+)-independent N-acyltransferase, H-rev107-like protein 5, HRAS-like suppressor 5

All UniProt accessions (4): F5H4Q3, Q96KN8, H0YGT7, H7BYL7

UniProt curated annotations — full annotation on UniProt →

Function. Exhibits both phospholipase A1/2 and acyltransferase activities. Shows phospholipase A1 (PLA1) and A2 (PLA2) activity, catalyzing the calcium-independent release of fatty acids from the sn-1 or sn-2 position of glycerophospholipids. Shows N-acyltransferase activity, catalyzing the calcium-independent transfer of a fatty acyl group at the sn-1 position of phosphatidylcholine (PC) and other glycerophospholipids to the primary amine of phosphatidylethanolamine (PE), forming N-acylphosphatidylethanolamine (NAPE), which serves as precursor for N-acylethanolamines (NAEs).

Subcellular location. Cytoplasm. Cytosol.

Tissue specificity. Highest expression level in testis and pancreas.

Similarity. Belongs to the H-rev107 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96KN8-1	1	yes
Q96KN8-2	2
Q96KN8-3	3

RefSeq proteins (3): NP_001140200, NP_001140201, NP_473449 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007053	LRAT_dom	Domain
IPR051496	H-rev107_PLA/AT	Family

Pfam: PF04970

Catalyzed reactions (Rhea), 8 shown:

• a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) (RHEA:15801)
• a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 2-acyl-sn-glycero-3-phosphocholine + a fatty acid + H(+) (RHEA:18689)
• 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine = N-hexadecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 2-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) (RHEA:45172)
• 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine = N-hexadecanoyl-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) (RHEA:45176)
• a 1,2-diacyl-sn-glycero-3-phosphoethanolamine + a 1,2-diacyl-sn-glycero-3-phosphocholine = an N-acyl-1,2-diacyl-sn-glycero-3-phosphoethanolamine + a 2-acyl-sn-glycero-3-phosphocholine + H(+) (RHEA:45188)
• a 1,2-diacyl-sn-glycero-3-phosphoethanolamine + a 1,2-diacyl-sn-glycero-3-phosphocholine = an N-acyl-1,2-diacyl-sn-glycero-3-phosphoethanolamine + a 1-acyl-sn-glycero-3-phosphocholine + H(+) (RHEA:45192)
• 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphocholine + 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine = N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) (RHEA:45476)
• 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine + 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine = N,1,2-tri-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1-hexadecanoyl-sn-glycero-3-phosphocholine + H(+) (RHEA:56504)

UniProt features (14 total): sequence variant 4, active site 3, region of interest 2, splice variant 2, chain 1, domain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96KN8-F1	62.39	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (3): 145; 157; 233 (acyl-thioester intermediate)

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1482839	Acyl chain remodelling of PE

MSigDB gene sets: 72 (showing top): GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GOBP_AMIDE_METABOLIC_PROCESS, GOBP_GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, WEBER_METHYLATED_HCP_IN_SPERM_UP, MODULE_95, WEBER_METHYLATED_HCP_IN_FIBROBLAST_DN, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_CARBOXYLIC_ESTER_HYDROLASE_ACTIVITY, GOMF_N_ACYLTRANSFERASE_ACTIVITY, GOMF_PHOSPHOLIPASE_A2_ACTIVITY, YOSHIMURA_MAPK8_TARGETS_UP

GO Biological Process (2): N-acylphosphatidylethanolamine metabolic process (GO:0070292), lipid metabolic process (GO:0006629)

GO Molecular Function (7): A2-type glycerophospholipase activity (GO:0004623), glycerophospholipid phospholipase A1 activity (GO:0008970), obsolete N-acyltransferase activity (GO:0016410), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746), hydrolase activity (GO:0016787)

GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
catalytic activity	2
cellular anatomical structure	2
phosphatidylethanolamine metabolic process	1
primary metabolic process	1
glycerophospholipase activity	1
carboxylic ester hydrolase activity	1
A1-type glycerophospholipase activity	1
binding	1
transferase activity	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

276 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLAAT5	NFKBIZ	Q9BYH8	790
PLAAT5	SCN8A	Q9UQD0	611
PLAAT5	SCN1A	P35498	570
PLAAT5	SPATA4	Q8NEY3	543
PLAAT5	DAGLA	Q9Y4D2	538
PLAAT5	SCN4B	Q8IWT1	515
PLAAT5	KLHDC3	Q9BQ90	467
PLAAT5	PLA2G4E	Q3MJ16	464
PLAAT5	NAPEPLD	Q6IQ20	454
PLAAT5	SCN5A	Q14524	447
PLAAT5	SCN2A	Q99250	445
PLAAT5	EIF3K	Q9UBQ5	444
PLAAT5	NAV1	Q8NEY1	436
PLAAT5	SFI1	A8K8P3	434
PLAAT5	SCN3A	Q9NY46	431
PLAAT5	MEA1	Q16626	431

IntAct

4 interactions, top by confidence:

A	B	Type	Score
PLAAT5	VCPIP1	psi-mi:“MI:0915”(physical association)	0.590

BioGRID (11): HRASLS5 (Two-hybrid), HRASLS5 (Two-hybrid), LOC155060 (Two-hybrid), VCPIP1 (Affinity Capture-MS), HRASLS5 (Biochemical Activity), VCPIP1 (Affinity Capture-MS), HRASLS5 (Two-hybrid), HRASLS5 (Two-hybrid), HRASLS5 (Two-hybrid), VCPIP1 (Affinity Capture-MS), APP (Reconstituted Complex)

ESM2 similar proteins: A2AKB4, A2RRU4, A4Q9F3, A4Q9F4, A5PJX4, A6NNM8, A8CVX7, D4A6L0, E1BBQ2, F1M5F3, O02695, O35141, P49796, P49797, P51509, P52734, P56182, P59644, P80560, P97260, P98174, Q12770, Q14679, Q15735, Q2KHI9, Q4R7H0, Q5EBH1, Q5MNU5, Q5SYB0, Q5T848, Q5XI57, Q6GQT6, Q6ZVT0, Q70EL4, Q80TE3, Q80UG8, Q8BUM9, Q8C419, Q8C4S8, Q8CDF7

Diamond homologs: A0A0R4IY06, D2KX21, P53816, P53817, Q4KLN5, Q5R611, Q8R3U1, Q96KN8, Q9BGL2, Q9CPX5, Q9HDD0, Q9JI61, Q9NWW9, Q9QZU4, Q9UL19, O95237, Q9JI60, Q96KN1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

38 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	36
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1135 predictions. Top by Δscore:

Variant	Effect	Δscore
11:63466134:T:C	donor_gain	1.0000
11:63466158:A:AC	donor_gain	1.0000
11:63466159:C:CC	donor_gain	1.0000
11:63466164:C:A	donor_gain	1.0000
11:63466181:A:AC	donor_gain	1.0000
11:63466182:C:CC	donor_gain	1.0000
11:63466368:CTCAC:C	acceptor_gain	1.0000
11:63466370:CAC:C	acceptor_gain	1.0000
11:63466373:C:CC	acceptor_gain	1.0000
11:63468352:CTTAC:C	donor_loss	1.0000
11:63468353:TTACT:T	donor_loss	1.0000
11:63468354:TACT:T	donor_loss	1.0000
11:63468355:A:AC	donor_gain	1.0000
11:63468356:C:CC	donor_gain	1.0000
11:63463592:CTAC:C	acceptor_gain	0.9900
11:63463596:C:T	acceptor_loss	0.9900
11:63466105:CACA:C	donor_loss	0.9900
11:63466106:ACAC:A	donor_loss	0.9900
11:63466107:CA:C	donor_loss	0.9900
11:63466108:A:C	donor_loss	0.9900
11:63466109:CC:C	donor_loss	0.9900
11:63466110:C:A	donor_loss	0.9900
11:63466159:CAGTT:C	donor_gain	0.9900
11:63466193:TGTTG:T	donor_gain	0.9900
11:63466369:TCACC:T	acceptor_gain	0.9900
11:63466371:AC:A	acceptor_gain	0.9900
11:63466372:CC:C	acceptor_gain	0.9900
11:63466381:C:CT	acceptor_gain	0.9900
11:63466381:C:T	acceptor_gain	0.9900
11:63468349:A:AC	donor_gain	0.9900

AlphaMissense

1739 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:63466134:T:A	R241S	0.999
11:63466134:T:G	R241S	0.999
11:63466135:C:G	R241T	0.998
11:63468403:C:A	W146C	0.998
11:63468403:C:G	W146C	0.998
11:63468405:A:G	W146R	0.998
11:63468405:A:T	W146R	0.998
11:63466150:A:G	F236S	0.997
11:63466181:A:G	Y226H	0.997
11:63468374:A:T	V156D	0.997
11:63468406:G:C	H145Q	0.997
11:63468406:G:T	H145Q	0.997
11:63468437:A:G	L135P	0.997
11:63466116:G:C	S247R	0.996
11:63466116:G:T	S247R	0.996
11:63466118:T:G	S247R	0.996
11:63466136:T:C	R241G	0.996
11:63466149:A:C	F236L	0.996
11:63466149:A:T	F236L	0.996
11:63466151:A:G	F236L	0.996
11:63466155:C:A	E234D	0.996
11:63466155:C:G	E234D	0.996
11:63466159:C:T	C233Y	0.996
11:63466161:G:C	N232K	0.996
11:63466161:G:T	N232K	0.996
11:63468402:C:G	A147P	0.996
11:63466110:C:A	Q249H	0.995
11:63466110:C:G	Q249H	0.995
11:63466147:A:T	V237D	0.995
11:63466150:A:C	F236C	0.995

dbSNP variants (sampled 300 via entrez): RS1000062038 (11:63465647 G>A,C), RS1000142795 (11:63473578 C>G), RS1000263319 (11:63492186 CAGTT>C), RS1000371253 (11:63467451 G>T), RS1000413915 (11:63461261 G>A), RS1000448818 (11:63471103 G>A), RS1000450434 (11:63470732 T>C), RS1000582112 (11:63492895 T>G), RS1000744825 (11:63463016 C>A), RS1000992747 (11:63479935 G>A), RS1001033379 (11:63464316 G>C), RS1001034638 (11:63487454 T>A,C,G), RS1001265717 (11:63462020 C>A,T), RS1001276022 (11:63490496 A>G), RS1001279685 (11:63480139 C>T)

Disease associations

OMIM: gene MIM:611474 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010512_9	Serum uric acid levels	1.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004761	uric acid measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4630850 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

35 potent at pChembl≥5 of 35 total, top 35 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.00	IC50	10	nM	CHEMBL4639478
7.50	IC50	31.62	nM	CHEMBL4639199
7.40	IC50	39.81	nM	CHEMBL4639242
7.40	IC50	39.81	nM	CHEMBL4643782
7.30	IC50	50.12	nM	CHEMBL4641977
7.20	IC50	63.1	nM	CHEMBL4643099
7.20	IC50	63.1	nM	CHEMBL4644464
7.10	IC50	79.43	nM	CHEMBL4636379
7.10	IC50	79.43	nM	CHEMBL4649677
7.10	IC50	79.43	nM	CHEMBL4636806
7.00	IC50	100	nM	CHEMBL4645342
7.00	IC50	100	nM	CHEMBL4633449
6.90	IC50	125.9	nM	CHEMBL4648272
6.80	IC50	158.5	nM	CHEMBL4640863
6.80	IC50	158.5	nM	CHEMBL4645578
6.70	IC50	199.5	nM	CHEMBL4636463
6.60	IC50	251.2	nM	CHEMBL4646350
6.60	IC50	251.2	nM	CHEMBL4644324
6.50	IC50	316.2	nM	CHEMBL4649884
6.50	IC50	316.2	nM	CHEMBL4643908
6.40	IC50	398.1	nM	CHEMBL4643675
6.20	IC50	631	nM	CHEMBL4645552
6.20	IC50	631	nM	CHEMBL4636625
6.10	IC50	794.3	nM	CHEMBL4642795
6.00	IC50	1000	nM	CHEMBL4638043
6.00	IC50	1000	nM	CHEMBL4649801
6.00	IC50	1000	nM	CHEMBL4646429
6.00	IC50	1000	nM	CHEMBL4636282
5.90	IC50	1259	nM	CHEMBL4641818
5.90	IC50	1259	nM	CHEMBL4632512
5.80	IC50	1585	nM	CHEMBL4641304
5.80	IC50	1585	nM	CHEMBL4639235
5.60	IC50	2512	nM	CHEMBL4640676
5.50	IC50	3162	nM	CHEMBL4640894
5.20	IC50	6310	nM	CHEMBL4634598

PubChem BioAssay actives

35 with measured affinity, of 67 total; 35 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
N-[2-(4-bromophenyl)ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0100	uM
2-oxo-5-phenyl-N-[2-[4-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]ethyl]pentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0316	uM
N-[2-(4-methylphenyl)ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0398	uM
2-oxo-N-[2-(4-phenoxyphenyl)ethyl]-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0398	uM
N-[2-(3-chlorophenyl)ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0501	uM
2-oxo-5-phenyl-N-[2-(4-pyrazin-2-yloxyphenyl)ethyl]pentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0631	uM
N-[2-(2,4-dichlorophenyl)ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0631	uM
N-[2-(4-methoxyphenyl)ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0794	uM
N-[2-[4-(2-chloropyrimidin-4-yl)oxyphenyl]ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0794	uM
2-oxo-5-phenyl-N-[2-[4-[[6-(trifluoromethyl)-3-pyridinyl]oxy]phenyl]ethyl]pentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.0794	uM
4-(3,4-dichlorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1000	uM
2-oxo-5-phenyl-N-(2-phenylethyl)pentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1000	uM
2-oxo-4-(4-phenoxyphenyl)-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1259	uM
2-oxo-6-phenyl-N-(2-phenylethyl)hexanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1585	uM
N-[2-(4-hydroxyphenyl)ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1585	uM
4-(4-chlorophenyl)-2-oxo-N-(4-phenylbutyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.1995	uM
2-oxo-5-phenyl-N-[2-(4-pyrimidin-2-yloxyphenyl)ethyl]pentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.2512	uM
N-benzyl-4-(4-chlorophenyl)-2-oxobutanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.2512	uM
N-[2-(3,4-dimethoxyphenyl)ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.3162	uM
2-oxo-N-(2-phenylethyl)-4-[4-(trifluoromethyl)phenyl]butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.3162	uM
4-(4-chlorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.3981	uM
(E)-4-(4-bromophenyl)-2-oxo-N-(2-phenylethyl)but-3-enamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.6310	uM
(E)-4-(4-chlorophenyl)-2-oxo-N-(2-phenylethyl)but-3-enamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.6310	uM
N-[2-(2-chlorophenyl)ethyl]-2-oxo-5-phenylpentanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	0.7943	uM
4-(4-chlorophenyl)-N-ethyl-2-oxobutanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.0000	uM
(E)-2-oxo-N-(2-phenylethyl)-4-(3-phenylphenyl)but-3-enamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.0000	uM
(E)-4-(4-methoxyphenyl)-2-oxo-N-(2-phenylethyl)but-3-enamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.0000	uM
2-oxo-4-phenyl-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.0000	uM
4-(3-chlorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.2589	uM
4-(4-methoxyphenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.2589	uM
4-(2-chlorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.5849	uM
4-(4-fluorophenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	1.5849	uM
4-(4-methylphenyl)-2-oxo-N-(2-phenylethyl)butanamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	2.5119	uM
(E)-4-(3-bromophenyl)-2-oxo-N-(2-phenylethyl)but-3-enamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	3.1623	uM
(E)-2-oxo-4-phenyl-N-(2-phenylethyl)but-3-enamide	1666054: Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	ic50	6.3096	uM

CTD chemical–gene interactions

14 total (human), top 14 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Nickel	decreases expression	2
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
Grape Seed Proanthocyanidins	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
incobotulinumtoxinA	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Catechin	affects cotreatment, increases expression	1
Folic Acid	decreases expression	1
Silicon Dioxide	increases expression	1
Tobacco Smoke Pollution	increases expression	1
Cadmium Chloride	increases expression	1

ChEMBL screening assays

12 unique, capped per target: 12 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4626915	Binding	Inhibition of full-length C-terminal FLAG-tagged human PLAAT5 expressed in HEK293T cell lysate preincubated for 30 mins followed by MB064 addition and measured after 20 mins by SDS-PAGE based ABPP analysis	Structure-Activity Relationship Studies of α-Ketoamides as Inhibitors of the Phospholipase A and Acyltransferase Enzyme Family. — J Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.